DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR NAFTIN
All Clinical Trials for Naftin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01580891 ↗ | Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis | Completed | Taro Pharmaceuticals USA | Phase 1 | 2012-05-01 | The objective of this study is to evaluate the efficacy and safety of the test formulation of Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed formulation Naftin® (Naftifine HCl) 1% Cream (Merz Pharmaceuticals) and placebo in patients with tinea pedis and to show the superiority of the active treatments over placebo when dosed once a day for 28 days. |
| NCT01885156 ↗ | Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris | Completed | Merz Pharmaceuticals, LLC | Phase 3 | 2013-08-01 | To see how well Naftin 1% cream works when applied once daily to the affected area. The results will be compared to those using a placebo cream, which is a cream with no active ingredient. Safety will also be measured. |
| NCT02132260 ↗ | Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis | Completed | Taro Pharmaceuticals USA | Phase 1 | 2013-08-01 | The objective of this study is to compare the efficacy and safety of the test formulation of Naftifine Hydrochloride Cream 2% to Naftin® (Naftifine Hydrochloride) 2% Cream in a 6 week study in patients with tinea pedis. |
| NCT02227290 ↗ | Pediatric Subjects With Tinea Corporis | Completed | Merz Pharmaceuticals, LLC | Phase 4 | 2014-08-01 | The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm). The results will be compared to those seen with a placebo cream which has no active ingredient. Safety of the cream will also be measured. |
| NCT02335255 ↗ | Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis | Completed | Taro Pharmaceuticals USA | Phase 1 | 2014-06-01 | To compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2% |
| NCT02466867 ↗ | An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis | Completed | Merz Pharmaceuticals, LLC | Phase 4 | 2014-01-01 | This is an open label, multi-center, multi-application pharmacokinetic study in pediatric subjects with tinea corporis. |
| NCT02633813 ↗ | BE Study of Naftifine HCL | Completed | GenZum Life Sciences LLC | Phase 3 | 2015-03-01 | The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details. V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the end of week 2 + 2 days). V3- Follow up visit (at the end of week 4 + 2 days). V4 - Test of cure visit ( at the end of week 6 + 4 days). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Naftin
Condition Name
Clinical Trial Locations for Naftin
Trials by Country
Clinical Trial Progress for Naftin
Clinical Trial Phase
Clinical Trial Sponsors for Naftin
Sponsor Name
